Dr. Eddie Garon, UCLA, reviews the controversial question of whether PD-L1 expression is a reliable enough biomarker to be used to select patients to receive or not receive immune checkpoint inhibitor therapy in lung cancer.
cancerGRACE.org/
- Should PD-L1 be Used as a Biomarker for Immunotherapy in Lung Cancer ( Download)
- Dr. Lilenbaum on PD-L1 as a Predictive Biomarker for Immunotherapy in Lung Cancer ( Download)
- Should PD-L1 be used as a biomarker for immunotherapy in bladder cancer ( Download)
- Dr. Goldberg on PD-L1 as a Biomarker in Lung Cancer ( Download)
- Understanding Immunotherapy for NSCLC with PD-1 and PD-L1 Biomarkers ( Download)
- Dr. Kim Discusses PD-L1 as a Biomarker in Lung Cancer ( Download)
- The role of PD-L1: is it accurate enough as a biomarker for immunotherapy response ( Download)
- Dr. Gandara Discusses PD-L1 as a Biomarker in Lung Cancer ( Download)
- Dr. Rizvi on PD-L1 as a Biomarker for Immunotherapy Agents in Lung Cancer ( Download)
- How does PD-L1 impact treatment options for lung cancer ( Download)
- Revisiting PD-L1 as an Immunotherapy Biomarker Across the Cancer Spectrum ( Download)
- Pembrolizumab and the significance of PD-L1 for lung cancer ( Download)
- PD-L1 as a Biomarker in Squamous Non-Small Cell Lung Cancer ( Download)
- The value of PD-L1 as a biomarker beyond lung cancers ( Download)
- Immunotherapy in Oncology and the Role of the PD-L1 Biomarker ( Download)
